|Bid||292.61 x 800|
|Ask||294.48 x 1100|
|Day's range||290.76 - 304.35|
|52-week range||75.35 - 464.00|
|Beta (5Y monthly)||-1.16|
|PE ratio (TTM)||16.26|
|Earnings date||09 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||322.30|
Last week, the U.S. Food and Drug Administration (FDA) authorized the use of "mix-and-match" COVID-19 vaccine boosters. Any person eligible to receive a booster won't have to stick with the same vaccine used in their primary vaccination. This FDA decision opens the door to even more of a contest between the three COVID-19 vaccines currently available in the U.S. That's especially the case between the two most widely adopted vaccines.
Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging update in the coronavirus vaccine.
Yahoo Finance's Anjalee Khemlani spoke with Pfizer CEO Albert Bourla about how the company increased production of COVID-19 vaccines to meet high demand.